Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
16 Aprile 2024 - 2:00PM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company focused on developing innovative
treatments for cancer patients, today announced that it has filed a
provisional patent application pertaining to the recent
advancements and optimizations Monopar has achieved with its
MNPR-101 radiopharmaceutical program.
The provisional patent titled “Antibody Radioisotope Constructs”
that was filed with the United States Patent and Trademark Office
(USPTO) outlines the MNPR-101-Zr construct, including variations on
the radioisotopes, linkers, and antibody which could enhance the
clinical profile of the construct, including properties such as its
stability and biodistribution. It also covers the formulations and
uses of MNPR-101-Zr, a zirconium-89 imaging radioisotope labeled
version of MNPR-101, Monopar’s proprietary first-in-class humanized
monoclonal antibody that is highly-selective against the urokinase
plasminogen activator receptor (uPAR).
Monopar expects this provisional patent application to further
strengthen its intellectual property around the MNPR-101
radiopharma program, under which the Company is aiming to develop
therapies for numerous hard-to-treat advanced cancers that express
uPAR. Monopar recently announced the initiation of its Phase 1
dosimetry clinical trial for MNPR-101-Zr in patients with advanced
cancers.
“Filing of this provisional patent application is aimed at
further protecting our novel MNPR-101 radiopharmaceutical program,”
said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
“This patent filing along with our earlier patent filings helps to
create a broad portfolio of intellectual property around this
program and potential future programs.”
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical
company focused on developing innovative treatments for cancer
patients. Monopar's pipeline consists of Phase 1-stage MNPR-101 for
radiopharmaceutical use in various advanced cancers; Phase 1b-stage
camsirubicin for the treatment of advanced soft tissue sarcoma; and
an early-stage camsirubicin analog, MNPR-202. For more information,
visit: www.monopartx.com and ir.monopartx.com/presentations.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Examples of these forward-looking
statements include: that the patent application outlines the
MNPR-101-Zr construct, including variations with the radioisotopes,
linkers and antibody which could enhance the clinical profile of
the construct, including properties such as its stability and
biodistribution; that Monopar expects this provisional patent
application to further strengthen its intellectual property to
protect the MNPR-101 radiopharma program; and that Monopar is
aiming to develop therapies for numerous hard-to-treat advanced
cancers that express uPAR. The forward-looking statements involve
risks and uncertainties including, but not limited to: that patent
applications may not result in allowed patents; that if allowed,
the patents may be too narrow in scope to provide protection needed
to successfully develop the radiopharma program; that we may expend
available funds sooner than anticipated or require additional
funding due to change in circumstances or unanticipated events;
that future preclinical or clinical data will not be as promising
as the data to date; not successfully enrolling the MNPR-101-Zr
Phase 1 clinical trial if at all; that MNPR-101-Zr and/or MNPR-101
conjugated to a therapeutic radioisotope may cause unexpected
serious adverse effects or fail to image or be effective against
the cancer tumors in humans; and the significant general risks and
uncertainties surrounding the research, development, regulatory
approval, and commercialization of imaging agents and therapeutics.
Actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks are described
more fully in Monopar's filings with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were
made. Monopar undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made. Any forward-looking
statements contained in this press release represent
Monopar’s views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent
date.
CONTACT:
Monopar Therapeutics Inc.Investor
Relations Kim R. Tsuchimoto Chief Financial
Officer kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
Grafico Azioni Monopar Therapeutics (NASDAQ:MNPR)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Monopar Therapeutics (NASDAQ:MNPR)
Storico
Da Set 2023 a Set 2024